Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center Randomized Phase III Study Evaluating 4 Cycles of Docetaxel, Doxorubicin and Cyclophosphamide Versus 4 Cycles of Vinorelbine and Capecitabine in Patients Not Sufficiently Responding to 2 Cycles of TAC and 4 Cycles of TAC Versus 6 Cycles of TAC in Patients Sufficiently Responding to 2 Cycles of TAC as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
Brief Summary: Primary objective of the study in patients without a sufficient sonographic response (i.e. iNC) to 2 cycles of TAC as preoperative treatment of operable (T\>/= 2cm, N0-2,M0) primary breast cancer: To determine the response rate determined by sonography (iRR = iCR+iPR) of further 4 cycles of docetaxel, doxorubicin and cyclophosphamide (TAC) and of 4 cycles of vinorelbine and capecitabine (NX) (TAC vs. NX)

Primary objective of the study in patients with a sufficient sonographic response (i.e. iRR = iPR or iCR) to the first 2 cycles of TAC as preoperative treatment of operable (T\>/=2cm, N0-2,M0) primary breast cancer: To determine the pCR rate of 6 cycles vs. 8 cycles of docetaxel, doxorubicin and cyclophosphamide (TAC x 6 vs. TAC x 8)


Options:
A: Arm Label: Arm A: EC-T; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: Epirubicin, Drug: Cyclophosphamide | Arm Label: Arm B: ET-X; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Capecitabine, Drug: Epirubicin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm A: EC-T, Arm B: ET-X | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm B: ET-X | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Arm A: EC-T, Arm B: ET-X | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A: EC-T
B: Arm Label: resp: 4xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: resp: 6xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: nonResp: 4xTAC; Type: EXPERIMENTAL; Interventions: Drug: TAC | Arm Label: nonResp: 4xNX; Type: EXPERIMENTAL; Interventions: Drug: NX | Intervention Type: DRUG; Name: TAC; Assigned to Arm(s): nonResp: 4xTAC, resp: 4xTAC, resp: 6xTAC | Intervention Type: DRUG; Name: NX; Assigned to Arm(s): nonResp: 4xNX
C: Arm Label: Capecitabine 1250 mg/m2; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Arm Label: Everolimus 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Everolimus 10 mg + Exemestane 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exemestane, Drug: Everolimus | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine 1250 mg/m2 | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): Everolimus 10 mg + Exemestane 25 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg, Everolimus 10 mg + Exemestane 25 mg
D: Arm Label: Arm A: bevacizumab and paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Biological: bevacizumab, Paclitaxel | Arm Label: Arm B: bevacizumab, cyclophosphamide and capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Cyclophosphamide, Capecitabine | Intervention Type: BIOLOGICAL; Name: bevacizumab, Paclitaxel; Assigned to Arm(s): Arm A: bevacizumab and paclitaxel | Intervention Type: BIOLOGICAL; Name: Bevacizumab, Cyclophosphamide, Capecitabine; Assigned to Arm(s): Arm B: bevacizumab, cyclophosphamide and capecitabine

Answer: B